1. |
Maschmeyer G. The changing epidemiology of invasive fungal infections: new threats[J]. Int J Antimicrob Agents, 2006, 27 (Suppl 1): 3-6.
|
2. |
Chakrabarti A, Chatterjee SS, Rao KL, et al. Recent experience with fungaemia: change in species distribution and azole resistance[J]. Scand J Infect Dis, 2009, 41(4): 275-284.
|
3. |
Almirante B, Rodriguez D, Park BJ, et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003[J]. J Clin Microbiol, 2005, 43(4): 1829-1835.
|
4. |
Castagnola E, Machetti M, Bucci B, et al. Antifungal prophylaxis with azole derivatives[J]. Clin Microbiol Infect, 2004, 10 (Suppl 1): 86-95.
|
5. |
刘正印, 李旭丽, 王爱霞. 院内真菌感染149例分析[J]. 中华医学杂志, 2003, 83(5): 50-53.
|
6. |
Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance[J]. J Hosp Infect, 2002, 50(4): 243-260.
|
7. |
Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10. 5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion[J]. J Clin Microbiol, 2010, 48(4): 1366-1377.
|
8. |
Diekema DJ, Messer SA, Boyken LB, et al. In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods[J]. J Clin Microbiol, 2009, 47(10): 3170-3177.
|
9. |
韩旭东, 黄虑. 深部真菌感染的临床和实验室诊断方案[J]. 上海医药, 2004, (10): 441-443.
|
10. |
周庭银. 临床微生物学诊断与图解[M]. 2版. 上海: 上海科学技术出版社, 2007: 318-319.
|
11. |
Medeiros EA, Lott TJ, Colombo AL, et al. Evidence for a pseudo-outbreak of Candida guilliermondii fungemia in a university hospital in Brazil[J]. J Clin Microbiol, 2007, 45(3): 942-947.
|
12. |
Girmenia C, Pizzarelli G, Cristini F, et al. Candida guilliermondii fungemia in patients with hematologic malignancies[J]. J Clin Microbiol, 2006, 44(7): 2458-2464.
|
13. |
Peman J, Bosch M, Canton E, et al. Fungemia due to Candida guilliermondii in a pediatric and adult population during a 12-year period[J]. Diagn Microbiol Infect Dis, 2008, 60(1): 109-112.
|
14. |
Miranda LN, van der Heijden IM, Costa SF, et al. Candida colonisation as a source for candidaemia[J]. J Hosp Infect, 2009, 72(1): 9-16.
|
15. |
Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus[J]. J Clin Microbiol, 2004, 42(10): 4419-4431.
|
16. |
Pfaller MA, Diekema DJ, Mendez M, et al. Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program[J]. J Clin Microbiol, 2006, 44(10): 3551-3556.
|
17. |
Barchiesi F, Spreghini E, Tomassetti S, et al. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis[J]. Antimicrob Agents Chemother, 2006, 50(8): 2719-2727.
|
18. |
Canton E, Peman J, Sastre M, et al. Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii[J]. Antimicrob Agents Chemother, 2006, 50(8): 2829-2832.
|
19. |
Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance[J]. J Clin Microbiol, 2008, 46(1): 150-156.
|
20. |
Savini V, Catavitello C, Di MI, et al. Pan-azole-resistant Candida guilliermondii from a leukemia patient’s silent funguria[J]. Mycopathologia, 2010, 169(6): 457-459.
|
21. |
Pfaller MA, Boyken L, Hollis RJ, et al. In vitro activities of anidulafungin against more than 2, 500 clinical isolates of Candida spp. , including 315 isolates resistant to fluconazole[J]. J Clin Microbiol, 2005, 43(11): 5425-5427.
|
22. |
Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2000 bloodstream Candida isolates in the United States[J]. Antimicrob Agents Chemother, 2003, 47(10): 3149-3154.
|
23. |
Kabbara N, Lacroix C, de Latour RP, et al. Breakthrough C, parapsilosis and C. Guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy[J]. Haematologica, 2008, 93(4): 639-640.
|